Boston Therapeutics Inc. (BTHE)
|Net Income (ttm)||-907,883|
|Trading Day||June 11|
|Day's Range||0.0247 - 0.0247|
|52-Week Range||0.0055 - 0.0600|
There are no news available yet.
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. The company's lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phas... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, BTHE's revenue was $9,336, a decrease of -42.83% compared to the previous year's $16,329. Losses were -$907,883, -75.42% less than in 2019.